Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vernakalant for Atrial Fibrillation
NCT00468767Phase 3Completed
- Sponsor
- ADVANZ PHARMA
- Start
- Aug 2003
- Primary completion
- Nov 2004
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Vernakalant with Placebo (2 arms). Primary endpoint: Proportion of patients with atrial fibrillation (AF) of 3 hours to 7 days duration who have treatment-induced conversion of AF to sinus rhythm for a minimum duration of one minute. Started Aug 2003; status: completed.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00468767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00468767.